article thumbnail

Ohio Gives Another Shot at Expanding Qualifying Conditions

Veriheal

Ohio is currently accepting petitions in an attempt to expand the list of qualifying conditions for medical cannabis. But this has failed in the past and could prevent measures from moving forward this time unless new research could be presented to sway the state medical board’s decision.

article thumbnail

Clinical Trial Finds Marijuana Oil to be Effective in Treating Fibromyalgia

The Joint Blog

We conclude that phytocannabinoids can be a low-cost and well-tolerated therapy for symptom relief and quality of life improvement in these patients, and we suggest that this therapy could be included as an herbal medicine option for the treatment of this condition in the Brazilian public health system.”. mg/mL of THC and 0.51 P < 0.001).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

article thumbnail

MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

Cannabis Law Report

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. During this presentation, Chris Chapman, M.D., MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes.

article thumbnail

Press Release: Silo Pharma Secures Patent that May be Used for Psychedelics Delivery Technology

Cannabis Law Report

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Presently, the company is working with researchers to build out these technologies and pave the way for clinical trials. Silo Pharma Inc.

article thumbnail

Relieving Effects of CBG In Different Medical Conditions

Cannabis Law Report

CBG or cannabigerol is obtained from immature cannabis plants since it is not present in fully developed plants. They concluded that CBG should be evaluated for clinical trials in individuals with IBD. All cannabinoids found in cannabis plants, including CBG, are present in broad-spectrum CBD oils, but not THC. .

article thumbnail

Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

Cannabis Law Report

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We